title: Retrospective evaluation of cetuximab-related adverse events from claims databases--methodological concerns.
authors.affiliation: Oncology Medical Strategy, Bristol-Myers Squibb, Plainsboro, NJ. Electronic address: sabine.maier@bms.com.
authors.forename: S
authors.initials: S
authors.lastname: Maier
authors.affiliation: Global Health Outcomes-Oncology, Eli Lilly and Company, Indianapolis, IN.
authors.forename: G
authors.initials: G
authors.lastname: Peltz
authors.affiliation: Oncology Health Outcomes Research, Bristol-Myers Squibb, Plainsboro, NJ.
authors.forename: J R
authors.initials: JR
authors.lastname: Penrod
authors.affiliation: Oncology Business Unit, Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: K P
authors.initials: KP
authors.lastname: Sugarman
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068818:Cetuximab; D003628:Database Management Systems; D006801:Humans; D007345:Insurance Claim Review; D012189:Retrospective Studies
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab